ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1871

Hospitalization Outcomes for Acute Myocardial Infraction and Acute Heart Failure in Patients with Idiopathic Inflammatory Myopathies (IIM) from 2016-2019 National Inpatient Sample (NIS)
Abstract Number: 1872

Outcome of Idiopathic Inflammatory Myositis Patients Who Received Rituximab: A Single Centre Retrospective Study
Abstract Number: 1873

Relationship Between Baseline Characteristics of Rheumatoid Arthritis and Types of Mortality: Study of Cohort Followed Prospectively
Abstract Number: 1874

Autoantibodies Are Common in Patients with Idiopathic Interstitial Lung Disease Suggesting a High Prevalence of Undiagnosed Autoimmune Connective Tissue Disease
Abstract Number: 1875

Assessment of Antibody Levels to Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) in Patients with Idiopathic Inflammatory Myopathies Receiving Treatment with Intravenous Immunoglobulin
Abstract Number: 1876

Efficacy of JAK Inhibitors in Idiopathic Inflammatory Myopathies (other Than Dermatomyositis)
Abstract Number: 1877

Nailfold Videocapillaroscopic Abnormalities Correlate with Disease Activity Measures and Cutaneous Damage in Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 1878

Identification of Serum Biomarkers Associated with Muscle Inflammation Detected on MRI in Polymyositis/dermatomyositis
Abstract Number: 1879

Analysis of the Association Between the Atrophic Factors Tripartite Motif Containing (TRIM) 63 and Atrogin-1 and the Clinical and Inflammatory Features of Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 1880

Vaccine Hesitancy Among Patients with Idiopathic Inflammatory Myopathies and Rheumatic Diseases in 2021-2022: A Comparative Analysis of COVID-19 Vaccination in Autoimmune Diseases Surveys
Abstract Number: 1881

Association Study Between anti-TIF1γ Antibody and Development of Neoplasia in Three Tertiary Hospitals
Abstract Number: 1882

Efficacy of Immune-apheresis in Patients with Inflammatory Myopathies: A Case Series
Abstract Number: 1883

Auto-antibodies Targeting Membrane Repair Proteins Enhances Myositis Phenotype
Abstract Number: 1884

Idiopathic Inflammatory Myopathies in Alaska Native/American Indian People in Alaska
Abstract Number: 1885

Histopathological Patterns of Muscle Involvement and Clinical Correlations in a Retrospective Cohort of Scleroderma Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].